PDG4 TILDRAKIZUMAB VERSUS GUSELKUMAB: A BUCHER INDIRECT COMPARISON

Abstract

This study aimed to address the comparative effectiveness of IL-23p19 inhibitors ILUMETRI® (tildrakizumab) and TREMFYA® (guselkumab), indicated for the treatment of moderate-to-severe plaque psoriasis. We report results of an indirect comparison to compare tildrakizumab 100 mg (dosed per approved label on weeks 0, 4 and every 12 weeks thereafter) and guselkumab 100 mg. We conducted a systematic literature review and Bucher indirect comparison of tildrakizumab and guselkumab, using placebo as a common comparator. Outcomes were evaluated at Weeks 12–16 and 24–28. A literature search identified 154 unique records including five studies that met eligibility criteria and were included in the analysis; two were tildrakizumab trials (reSURFACE 1 and reSURFACE 2) and three guselkumab trials (VOYAGE 1, VOYAGE 2, and Ohtsuki et al.). Analysis was based on the intent-to-treat (ITT) population and for all outcomes, the number of events reported were analysed as a proportion of the number of patients randomised to ensure consistency across trials. Outcomes assessed were: severity of psoriasis as defined by the Psoriasis Area and Severity Index (PASI) 75 and PASI 90, frequency of serious adverse events (SAEs), and treatment discontinuations. There was no statistically significant difference between guselkumab and tildrakizumab for PASI 75, PASI 90, SAE and rate of discontinuations at either timepoint at Weeks 12–16 and Weeks 24–28. This indirect comparison does not provide evidence that one treatment is superior to the other.